Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial

JH Kempen; ML Van Natta; MM Altaweel; JP Dunn; DA Jabs; SL Lightman; JE Thorne; JT Holbrook; GJ Jaffe; B Branchaud; P Hahn; L Koreen; EM Lad; P Lin; JN Martel; N Serrano; C Skalak; L Vajzovic; C Baer; J Bryant; S Chavala; M Cusick; S Day; P Dayani; J Ehlers; M Kesen; A Lee; A Melamud; JA Qureshi; AW Scott; RF See; RK Shuler; M Wood; S Yeh; A Fernandes; D Gibbs; D Leef; DF Martin; S Srivastava; H Begum; J Boring; KL Brotherson; B Burkholder; NJ Butler; D Cain; MA Cook; D Emmert; JR Graul; M Herring; A Laing; TG Leung; MC Mahon; A Moradi; A Nwankwo; TL Ostheimer; T Reed; E Arnold; PM Barnabie; ML Belair; SG Bolton; JB Brodine; DM Brown; LM Brune; A Galor; T Gan; A Jacobowitz; M Kapoor; S Kedhar; S Kim; HA Leder; AG Livingston; Y Morton; K Nolan; GB Peters; P Soto; R Stevenson; M Tarver-Carr; Y Wang; CS Foster; SD Anesi; L Bruner; O Ceron; DM Hinkle; N Persons; B Wentworth; S Acevedo; F Anzaar; T Cesca; A Contero; K Fitzpatrick; F Goronga; J Johnson; KQ Lebron; D Marvell; C Morgan; N Patel; J Pinto; SS Siddique; J Sprague; T Yilmaz

Journal article

Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial

JH Kempen, ML Van Natta, MM Altaweel, JP Dunn, DA Jabs, SL Lightman, JE Thorne, JT Holbrook, GJ Jaffe, B Branchaud, P Hahn, L Koreen, EM Lad, P Lin, JN Martel, N Serrano, C Skalak, L Vajzovic, C Baer, J Bryant Show all

American Journal of Ophthalmology | Published : 2015

DOI: 10.1016/j.ajo.2015.09.017

Abstract

Purpose To identify factors associated with best-corrected visual acuity (BCVA) presentation and 2-year outcome in 479 intermediate, posterior, and panuveitic eyes. Design Cohort study using randomized controlled trial data. Methods Multicenter Uveitis Steroid Treatment (MUST) Trial masked BCVA measurements at baseline and at 2 years follow-up used gold-standard methods. Twenty-three clinical centers documented characteristics per protocol, which were evaluated as potential predictive factors for baseline BCVA and 2-year change in BCVA. Results Baseline factors significantly associated with reduced BCVA included age ≥50 vs 10 vs grade 0; cataract; macular thickening; and exudative retinal de..

View full abstract

University of Melbourne Researchers

Lyndell Lim Author

Grants

Awarded by National Eye Institute

Funding Acknowledgements

THIS STUDY IS SUPPORTED BY NATIONAL EYE INSTITUTE (BETHESDA, MARYLAND) COLLABORATIVE Agreements U10EY014655 (Dr Jabs), U10EY014660 (Dr Holbrook), and U10EY014656 (Dr Altaweel). Bausch & Lomb (Rochester, New York) provided support to the study in the form of donation of fluocinolone implants for patients randomized to implant therapy who were uninsured or otherwise unable to pay for implants, or were located at a site where implants could not be purchased (eg, in the United Kingdom). Additional support was provided by Research to Prevent Blindness (New York, New York), the Paul and Evanina Mackall Foundation (New York, New York), and the Lois Pope Life Foundation (New York, New York). A representative of the National Eye Institute participated in the conduct of the study, including the study design and the collection, management, analysis, and interpretation of the data, as well as in the review and approval of this manuscript. Financial Disclosures: In the last 3 years, John H. Kempen has served as a consultant for AbbVie (North Chicago, Illinois), Alcon (Fort Worth, Texas), Allergan (Irvine, California), Can-Fite (Peta-Tikva, Israel), Clearside (Alpharetta, Georgia), Lux Biosciences (Jersey City, New Jersey), Roche (Basel, Switzerland), and Xoma.(Berkeley, California); Douglas A. Jabs is a consultant for Santen, Inc (Osaka, Japan) and serves on Data and Safety Monitoring Committee's for Novartis (Basel, Switzerland) and Applied Genetic Technologies Corporation (Alachua, Florida); Susan L. Lightman has served as a consultant and is a grantee from Allergan, GSK (London, United Kingdom), and Bayer (Leverkusen, Germany); and Jennifer E. Thorne is a consultant for AbbVie, Gilead Sciences (Foster City, California), and Xoma and receives research funding from Allergan. The following authors have no financial disclosures: Mark L. Van Natta, Michael M. Altaweel, James P. Dunn, and Janet T. Holbrook. All authors attest that they meet the current ICMJE criteria for authorship.